Scholarlink

Objective <p>Oxaliplatin (L-OHP) is effective in the treatment of metastatic colorectal cancer (mCRC). However, given concerns about the possible impact of L-OHP-based chemotherapy regimens in the face of physical functional decline, the question of whether they should be actively recommended for elderly patients remains unclear. This study evaluated the relationship between the Geriatric 8 (G8) score, which assesses overall function in the elderly, and the efficacy and safety of L-OHP-based chemotherapy regimens.</p> Methods <p>This retrospective study included mCRC patients aged ≥ 70&#xa0;years who received L-OHP as first-line therapy between January 2017 and December 2022. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was incidence of adverse events (Grade ≥ 2). Patients were classified into high (≥ 14 points) and low (&lt; 14 points) G8 score groups for comparison.</p> Results <p>A total of 55 patients were included. Median PFS was significantly longer in the high G8 score group compared to the low G8 score group (12.4 vs. 6.0&#xa0;months, <i>P</i> = 0.034). No significant difference in OS was observed (27.9 vs. 29.8&#xa0;months, <i>P</i> = 0.833). The overall incidence of adverse events was comparable, but nausea incidence tended to be higher in the low G8 score group (0% vs. 25.5%, <i>P</i> = 0.096).</p> Conclusion <p>The G8 score may serve as a useful prognostic factor in elderly mCRC patients receiving L-OHP. Those with lower G8 scores may be at higher risk of L-OHP-induced nausea.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Geriatric 8 score as a prognostic factor of the efficacy and safety of oxaliplatin-based chemotherapy in elderly patients with metastatic colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月30日

查看全文
  • Koki Hara,
  • Wakana Chikaishi,
  • Yunami Yamada,
  • Hironori Fujii,
  • Jesse Yu Tajima,
  • Hirotoshi Iihara,
  • Akitaka Makiyama,
  • Daichi Watanabe,
  • Koichi Ohata,
  • Chiemi Hirose,
  • Ryo Kobayashi,
  • Akio Suzuki,
  • Nobuhisa Matsuhashi

摘要

Objective

Oxaliplatin (L-OHP) is effective in the treatment of metastatic colorectal cancer (mCRC). However, given concerns about the possible impact of L-OHP-based chemotherapy regimens in the face of physical functional decline, the question of whether they should be actively recommended for elderly patients remains unclear. This study evaluated the relationship between the Geriatric 8 (G8) score, which assesses overall function in the elderly, and the efficacy and safety of L-OHP-based chemotherapy regimens.

Methods

This retrospective study included mCRC patients aged ≥ 70 years who received L-OHP as first-line therapy between January 2017 and December 2022. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was incidence of adverse events (Grade ≥ 2). Patients were classified into high (≥ 14 points) and low (< 14 points) G8 score groups for comparison.

Results

A total of 55 patients were included. Median PFS was significantly longer in the high G8 score group compared to the low G8 score group (12.4 vs. 6.0 months, P = 0.034). No significant difference in OS was observed (27.9 vs. 29.8 months, P = 0.833). The overall incidence of adverse events was comparable, but nausea incidence tended to be higher in the low G8 score group (0% vs. 25.5%, P = 0.096).

Conclusion

The G8 score may serve as a useful prognostic factor in elderly mCRC patients receiving L-OHP. Those with lower G8 scores may be at higher risk of L-OHP-induced nausea.